Merger With Cempra Takes Melinta Public, Will Help Launch Baxdela
In all-stock transaction, troubled Cempra will merge with privately held Melinta to create a fully integrated anti-infectives company.
You may also be interested in...
Melinta: A Pure-Play Antibiotics Specialist Rises
CEO Daniel Wechsler talked with Scrip about being a pure-play specialist in the challenging antibiotics market, following the acquisition of The Medicines Co.'s anti-infectives franchise and a reverse merger with Cempra last year.
Melinta Expands Portfolio, TMC Narrows Focus To LDL Reduction With Anti-Infective Deal
A transaction bringing newly public Melinta three anti-infective products and a related sales force from The Medicines Co. will enable the latter to downsize and focus on its Phase III PCSK9 inhibitor inclisiran.
Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line
Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.